News

Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.

The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.

Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.

Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.

Here's the latest on the cyclosporiasis and jalapeño-linked Salmonella case numbers, plus an update on the resolved avocado inspection halt. Also included is information on a bacterial infection linked to shellfish, and a look at efforts affecting cyclosporiasis research.

Adding bismuth to amoxicillin-vonoprazan increased efficacy of the combination for H pylori, and exceeded that of clarithromycin-based triple therapy without contributing to clarithromycin resistance.

In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.

Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.

The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.

The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.

The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.

GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.

Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.

Here is a comprehensive list of vaccines approved this year as well as background information on the clinical data for each of them.

A shortened, response-tailored antibiotic treatment of infective endocarditis was associated with longer survival, but higher incidence of relapse.

Although azithromycin or another antibiotic is given to an estimated one of four preschool-age children in emergency departments for wheezing episodes, it failed to demonstrate benefit in a new multi-center trial.

In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.

The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.

The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.

The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.

Gavin Harris, MD, provides some context around what is happening in the Democratic Republic of Congo regarding the outbreak including the country’s inherent challenges as well as discussing the latest in testing, vaccines, and treatments of this rare strain of Ebola.

Venky Soundararajan, PhD, co-founder and chief scientific officer of nference, explains what the semaglutide-COVID-19/influenza data can and can't tell clinicians about mechanism, bias, and the evidence bar before it should shape prescribing.

The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.

A retrospective cohort study of more than 29 million patients found adults with prior semaglutide use had significantly lower 30-day mortality, hospitalization, and acute kidney injury after COVID-19 or influenza infection compared with a metformin comparator group.

Two Lancaster County residents have died from measles-associated complications, the state's first measles deaths in 35 years.

The phase 3 priMe trial found the investigational vaccine did not demonstrate noninferiority for preventing tuberculosis infection, though the study authors cited surrogate end point and exposure-imbalance issues that complicate interpretation.

Federal health officials are tracking simultaneous multistate outbreaks tied to frozen organic blueberries sold at Publix and alfalfa sprouts sold under the Calco and Everything Sprouts brands, together sickening more than 65 people across roughly 20 states.

Histoplasma, Blastomyces, and Coccidioides remain underrecognized causes of community-acquired pneumonia, particularly when clinical presentation mimics bacterial disease. Knowing where to look and when reshapes the diagnostic and therapeutic approach.